THE FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH

KarXT, a new schizophrenia drug targeting muscarinic receptors, has sparked excitement in psychiatric medicine, with several similar drugs in development. However, the failure of a highly anticipated muscarinic drug, emraclidine, in a trial raises questions about the future of this approach. KarXT's success has revived interest in muscarinic drugs, but the development process remains challenging and uncertain.